Study of Licarbazepine in the Treatment of Manic Episodes of Bipolar Disorder

• Status: Completed
• Trial end date: 2006-08-01
• Target enrollment: 0
• Participant gender: All

Summary

This purpose of this study is to evaluate the safety and efficacy of Licarbazepine for the treatment of manic episodes of bipolar disorder.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Novartis Pharmaceuticals

Criteria

Inclusion Criteria:

• Diagnosis of bipolar disorder (type I) with manic or mixed episodes (including patients with/without psychotic features or with/without a history of rapid cycling)

• In need of psychiatric treatment

• Cooperation and willingness to complete all aspects of the study

Exclusion Criteria:

• Current diagnosis other than bipolar I disorder

• History of schizophrenia or schizoaffective disorder

• Drug dependence within 1 month prior to study start or testing positive in a urine drug test

• Suicide attempt within 1 month prior to study start or at immediate risk of harm to self or others

• Any form of psychotherapy within 1 month prior to study start